Radiat Oncol J.
2019 Dec;37(4):265-270. 10.3857/roj.2019.00409.
Evaluation of response to stereotactic radiosurgery in patients with radioresistant brain metastases
- Sayan M
- Zoto Mustafayev T
- Sahin B
- Kefelioglu ESS
- Wang SJ
- Kurup V
- Balmuk A
- Gungor G
- Ohri N
- Weiner J
- Ozyar E
- Atalar B
- Affiliations
-
- 1Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. ms2641@cinj.rutgers.edu
- 2Department of Radiation Oncology, School of Medicine, Mehmet Ali Aydinlar Acibadem University, Istanbul, Turkey.
- 3Institute of Health Sciences, Mehmet Ali Aydinlar Acibadem University, Istanbul, Turkey.
- 4School of Medicine, Mehmet Ali Aydinlar Acibadem University, Istanbul, Turkey.
- KMID: 2468735
- DOI: http://doi.org/10.3857/roj.2019.00409
Abstract
- PURPOSE
Renal cell carcinoma (RCC) and melanoma have been considered "˜radioresistant' due to the fact that they do not respond to conventionally fractionated radiation therapy. Stereotactic radiosurgery (SRS) provides high-dose radiation to a defined target volume and a limited number of studies have suggested the potential effectiveness of SRS in radioresistant histologies. We sought to determine the effectiveness of SRS for the treatment of patients with radioresistant brain metastases.
MATERIALS AND METHODS
We performed a retrospective review of our institutional database to identify patients with RCC or melanoma brain metastases treated with SRS. Treatment response were determined in accordance with the Response Evaluation Criteria in Solid Tumors.
RESULTS
We identified 53 radioresistant brain metastases (28% RCC and 72% melanoma) treated in 18 patients. The mean target volume and coverage was 6.2 ± 9.5 mL and 95.5% ± 2.9%, respectively. The mean prescription dose was 20 ± 4.9 Gy. Forty lesions (75%) demonstrated a complete/partial response and 13 lesions (24%) with progressive/stable disease. Smaller target volume (p < 0.001), larger SRS dose (p < 0.001), and coverage (p = 0.008) were found to be positive predictors of complete response to SRS.
CONCLUSION
SRS is an effective management option with up to 75% response rate for radioresistant brain metastases. Tumor volume and radiation dose are predictors of response and can be used to guide the decision-making for patients with radioresistant brain metastases.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Stereotactic radiosurgery for brain metastases
- Stereotactic Radiosurgery for Metastatic Brain Tumor
- Systemic therapy augmented by radiotherapy (STAR) effect for brain metastases in a BRAF-mutated melanoma patient with prolonged survival: a case report
- Fractionated Stereotactic Radiosurgery for Brain Metastases Using the Novalis Tx® System
- Introduction to Radiosurgery
